https://www.surinamehealthcarepress.com/article/910324477-inspiremd-reports-first-quarter-2026-financial-results Suriname Healthcare Press en PressRelease 2026-05-04T20:05:00+00:00 InspireMD Reports First Quarter 2026 Financial Results https://ml-eu.globenewswire.com/media/5aefda10-5578-41c7-a1c0-9c4b700687c0/small/inspiremd-jpg.jpg https://www.surinamehealthcarepress.com/article/910324487-option-care-health-to-participate-in-the-bank-of-america-health-care-conference Suriname Healthcare Press en PressRelease 2026-05-04T20:05:00+00:00 Option Care Health to Participate in the Bank of America Health Care Conference https://ml.globenewswire.com/media/YWM2YTg3MzEtODAyYy00ZmVkLWE5YzUtNDk2YjA4MDU0ZWIxLTEwMTk5NzQtMjAyNi0wNS0wNC1lbg==/tiny/Option-Care-Health-Inc-.png https://www.surinamehealthcarepress.com/article/910324540-kyntra-bio-to-report-first-quarter-2026-financial-results Suriname Healthcare Press en PressRelease 2026-05-04T20:05:00+00:00 Kyntra Bio to Report First Quarter 2026 Financial Results https://ml.globenewswire.com/media/9105c1e9-d9e3-4b68-9fc8-261fed7db250/small/kyntra-bio-r-rgb-png.png https://www.surinamehealthcarepress.com/article/910324650-capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12 Suriname Healthcare Press en PressRelease 2026-05-04T20:05:00+00:00 Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 https://ml.globenewswire.com/media/16ce4387-5b8f-447c-96b8-7c453633f9bf/small/getimage-48-768x274-png.png https://www.surinamehealthcarepress.com/article/910324654-lexicon-pharmaceuticals-announces-100-million-loan-facility-with-hercules-capital Suriname Healthcare Press en PressRelease 2026-05-04T20:05:00+00:00 Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital https://ml.globenewswire.com/media/afcf3b59-ca71-40ed-9226-a0901bf4d13b/small/logo-jpg.jpg https://www.surinamehealthcarepress.com/article/910324720-aktis-oncology-initiates-phase-1b-clinical-trial-for-aky-2519-a-b7-h3-miniprotein-radioconjugate-in-metastatic-castration-resistant-prostate-cancer Suriname Healthcare Press en PressRelease 2026-05-04T20:05:00+00:00 Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) https://ml.globenewswire.com/media/490bbb9a-2b27-4a72-8d7a-333387326d8b/small/aktis-rgb-png.png https://www.surinamehealthcarepress.com/article/910324723-akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Suriname Healthcare Press en PressRelease 2026-05-04T20:05:00+00:00 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.surinamehealthcarepress.com/article/910324766-oric-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-updates Suriname Healthcare Press en PressRelease 2026-05-04T20:05:00+00:00 ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates https://ml.globenewswire.com/media/acbc0ad2-7a44-4ee7-b729-ab92d57ffafb/small/oric-png.png https://www.surinamehealthcarepress.com/article/910324634-inspire-medical-systems-inc-announces-first-quarter-2026-financial-results-and-updates-2026-guidance Suriname Healthcare Press en PressRelease 2026-05-04T20:02:00+00:00 Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance https://ml.globenewswire.com/media/194e83a5-3f7e-4805-88ce-da2e0ab594df/small/inspire-primary-logo-rgb-daylight-002-png.png https://www.surinamehealthcarepress.com/article/910324758-ocugen-announces-private-offering-of-115-million-of-convertible-senior-notes Suriname Healthcare Press en PressRelease 2026-05-04T20:01:51+00:00 Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://www.surinamehealthcarepress.com/article/910324495-praxis-precision-medicines-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026-and-participate-in-upcoming-investor-conference Suriname Healthcare Press en PressRelease 2026-05-04T20:01:00+00:00 Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.surinamehealthcarepress.com/article/910324509-fibrobiologics-reports-preclinical-data-showing-fibroblast-spheroids-may-actively-reprogram-the-burn-wound-environment-to-drive-healing-and-reduce Suriname Healthcare Press en PressRelease 2026-05-04T20:01:00+00:00 FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://www.surinamehealthcarepress.com/article/910324510-biodesix-announces-first-quarter-2026-results-and-highlights Suriname Healthcare Press en PressRelease 2026-05-04T20:01:00+00:00 Biodesix Announces First Quarter 2026 Results and Highlights https://ml.globenewswire.com/media/b2fd8e3c-ff04-47d9-938d-93c9c961ccc3/small/bdsx-logo-1200x240-png.png https://www.surinamehealthcarepress.com/article/910324629-hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares Suriname Healthcare Press en PressRelease 2026-05-04T20:01:00+00:00 Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://ml.globenewswire.com/media/M2UyM2ExNWYtYTJjYi00M2RhLTkwZGEtNjZlYTUyMzI4NTI4LTEzMjE4MjEtMjAyNi0wNS0wNC1lbg==/tiny/Hemab-Therapeutics-Inc-.png https://www.surinamehealthcarepress.com/article/910324649-senseonics-announces-closing-of-92-million-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares Suriname Healthcare Press en PressRelease 2026-05-04T20:01:00+00:00 Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares  https://ml.globenewswire.com/media/7f64f449-dd5d-4bd1-9504-82adb3846669/small/logo-png.png https://www.surinamehealthcarepress.com/article/910324596-cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive Suriname Healthcare Press en PressRelease 2026-05-04T20:00:00+00:00 Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 https://ml.globenewswire.com/media/52e2be9f-e9e3-43af-a747-123fdcac4253/small/cytokinetics-png.png https://www.surinamehealthcarepress.com/article/910324676-providence-saint-john-s-health-center-reinforces-its-commitment-to-maternal-and-newborn-care-through-newly-named-maria-shriver-labor-delivery-and Suriname Healthcare Press en PressRelease 2026-05-04T19:42:13+00:00 Providence Saint John’s Health Center Reinforces its Commitment to Maternal and Newborn Care Through Newly Named Maria Shriver Labor, Delivery and Family Wellness Unit https://ml.globenewswire.com/media/7f052405-cf27-4729-904d-589a86a37d33/medium/think-pink-for-women-s-wellness-supporting-providence-saint.jpg https://www.surinamehealthcarepress.com/article/910306648-aegis-treatment-centers-launches-mobile-medication-vehicle-to-expand-access-to-addiction-care-in-pasadena-and-surrounding-areas Suriname Healthcare Press en PressRelease 2026-05-04T18:45:00+00:00 Aegis Treatment Centers Launches Mobile Medication Vehicle to Expand Access to Addiction Care in Pasadena and Surrounding Areas https://ml.globenewswire.com/media/ZTNhY2M2NTAtZDZhMy00MDM4LWJmMjEtYzhiYzkwOGIwMDcyLTEyNzQyMTYtMjAyNi0wNS0wNC1lbg==/tiny/Pinnacle-Treatment-Centers.png https://www.surinamehealthcarepress.com/article/910291496-sync-supplement-claims-evaluated-the-revive-daily-sunlight-loophole-formula-for-healthy-circadian-rhythm-support Suriname Healthcare Press en PressRelease 2026-05-04T17:18:28+00:00 SYNC Supplement Claims Evaluated: The Revive Daily Sunlight Loophole Formula for Healthy Circadian-Rhythm Support https://zingfast.com/wp-content/uploads/2026/05/SYNC-Supplement.jpg https://www.surinamehealthcarepress.com/article/910291435-sace-launches-out-in-the-open-campaign-for-sexual-violence-awareness-month Suriname Healthcare Press en PressRelease 2026-05-04T17:10:11+00:00 SACE Launches “Out in the Open” Campaign for Sexual Violence Awareness Month https://ml.globenewswire.com/media/M2ZhZGI5YjgtZTI2NS00NmY1LTgzYTEtMmFhMTZmNzI3YmM3LTUwMDE2MjA1My0yMDI2LTA1LTA0LWVu/tiny/Sexual-Assault-Center-of-Edmon.png https://www.surinamehealthcarepress.com/article/910291473-eascra-biotech-welcomes-dr-anne-yau-as-life-science-research-scientist Suriname Healthcare Press en PressRelease 2026-05-04T17:04:04+00:00 Eascra Biotech Welcomes Dr. Anne Yau as Life Science Research Scientist https://ml.globenewswire.com/media/1eda41c1-8c5d-43f0-9198-b0a1570f47e6/medium/dr-anne-yau.jpg https://www.surinamehealthcarepress.com/article/910278476-confluent-medical-technologies-announces-nitinol-wire-center-of-excellence Suriname Healthcare Press en PressRelease 2026-05-04T16:00:00+00:00 Confluent Medical Technologies Announces Nitinol Wire Center of Excellence https://ml.globenewswire.com/media/028bf7c1-4bf6-4b3b-8629-3235829b9477/small/confluent-logo-color-png.png https://www.surinamehealthcarepress.com/article/910272567-when-the-heart-can-t-keep-up-what-to-know-about-heart-failure Suriname Healthcare Press en PressRelease 2026-05-04T15:28:08+00:00 When the Heart Can’t Keep Up: What to Know About Heart Failure https://ml.globenewswire.com/Resource/Download/79158b1b-2b4f-4818-8faa-7574106d7290/17877-1.jpg https://www.surinamehealthcarepress.com/article/910272536-timelycare-acquires-alongside-to-expand-continuous-student-support-with-clinician-powered-ai-coaching Suriname Healthcare Press en PressRelease 2026-05-04T15:00:00+00:00 TimelyCare Acquires Alongside to Expand Continuous Student Support with Clinician-Powered AI Coaching https://ml.globenewswire.com/media/51377623-fd82-411b-9c2c-22d85af45622/medium/alongside-by-timelycare.png https://www.surinamehealthcarepress.com/article/910272574-awareness-is-key-3-steps-to-help-recognize-stroke-signs-and-risks-for-better-outcomes Suriname Healthcare Press en PressRelease 2026-05-04T14:59:07+00:00 Awareness is Key: 3 Steps to Help Recognize Stroke Signs and Risks for Better Outcomes https://ml.globenewswire.com/Resource/Download/71a30026-5d47-467d-b6d5-c5bf1d2b31d8/17855-1.jpg https://www.surinamehealthcarepress.com/article/910266581-flyte-increases-capacity-and-launches-hiring-initiative-as-spirit-airlines-shutdown-disrupts-u-s-air-travel Suriname Healthcare Press en PressRelease 2026-05-04T14:30:00+00:00 Flyte Increases Capacity and Launches Hiring Initiative as Spirit Airlines Shutdown Disrupts U.S. Air Travel https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://www.surinamehealthcarepress.com/article/910266602-chopped-leaf-launches-new-premium-sandwich-lineup-featuring-toasted-ciabatta-creations Suriname Healthcare Press en PressRelease 2026-05-04T14:24:08+00:00 Chopped Leaf Launches New Premium Sandwich Lineup Featuring Toasted Ciabatta Creations https://ml.globenewswire.com/media/ZGY0ZWI1OTEtNGNhNy00ZmFjLThhN2EtODM5YTdmNmVkMDUxLTEyNzIxMjEtMjAyNi0wNS0wNC1lbg==/tiny/The-Chopped-Leaf.png https://www.surinamehealthcarepress.com/article/910262632-mmi-s-symani-surgical-system-treats-first-alzheimer-s-patient-in-groundbreaking-remind-study Suriname Healthcare Press en PressRelease 2026-05-04T14:10:00+00:00 MMI’s Symani Surgical System Treats First Alzheimer’s Patient in Groundbreaking REMIND Study https://ml.globenewswire.com/media/e9325bed-8fcb-4abf-b66e-6f076014b0fb/small/mmi-logo-stacked-tagline-positive-rgb1-png.png https://www.surinamehealthcarepress.com/article/910262611-research-on-new-class-of-treatments-for-ovarian-cancer-receives-725-000-in-funding-from-ovarian-cancer-canada-to-become-clinical-trial-ready Suriname Healthcare Press en PressRelease 2026-05-04T14:00:00+00:00 Research on new class of treatments for ovarian cancer receives $725,000 in funding from Ovarian Cancer Canada to become “clinical trial-ready” https://ml.globenewswire.com/media/YWY2NGZiYWEtODcyZC00Y2I5LThkZGEtYmM5ZjlkYzFkNDMzLTEzMTI5NjUtMjAyNi0wNS0wNC1lbg==/tiny/Ovarian-Cancer-Canada.png https://www.surinamehealthcarepress.com/article/910262626-spring-allergies-hit-lungs-hard-doctor-of-pharmacy-explains-what-actually-helps Suriname Healthcare Press en PressRelease 2026-05-04T14:00:00+00:00 Spring Allergies Hit Lungs Hard: Doctor of Pharmacy Explains What Actually Helps https://ml.globenewswire.com/media/13a92186-d8d0-4494-9e0a-5fc1d2e363ee/small/betterbrand-logo-new-png.png https://www.surinamehealthcarepress.com/article/910262571-xpress-wellness-acquires-wichita-s-mental-health-clinic-midwest-counseling-services Suriname Healthcare Press en PressRelease 2026-05-04T13:57:00+00:00 Xpress Wellness Acquires Wichita’s Mental Health Clinic Midwest Counseling Services https://ml.globenewswire.com/media/3c8097b3-a387-4dd0-8063-4f48aad75699/small/xpress-wellness-logo-png.png https://www.surinamehealthcarepress.com/article/910258243-cdc-host-tt-certification-for-siemens-healthineers-total-testosterone-test-expands-patient-access-to-gold-standard-equivalent-results Suriname Healthcare Press en PressRelease 2026-05-04T13:30:00+00:00 CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results https://ml.globenewswire.com/media/c5f289d1-b23c-41d2-bfe1-0121523d54b6/small/ https://www.surinamehealthcarepress.com/article/910258255-coherus-oncology-to-report-first-quarter-2026-financial-results-on-may-11-2026 Suriname Healthcare Press en PressRelease 2026-05-04T13:30:00+00:00 Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 https://ml.globenewswire.com/media/07437af0-8ae3-48cf-952b-18bc6b99ca7c/small/coherus-onc-logo-rgb-150-png.png https://www.surinamehealthcarepress.com/article/910258286-alpha-tau-announces-100-local-disease-control-rate-and-favorable-safety-profile-observed-in-alpha-dart-pancreatic-cancer-trials-presented-at-ddw Suriname Healthcare Press en PressRelease 2026-05-04T13:17:21+00:00 Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026 https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.surinamehealthcarepress.com/article/910253033-greece-launches-world-s-first-national-wildfire-satellite-system-with-ororatech Suriname Healthcare Press en PressRelease 2026-05-04T13:04:00+00:00 Greece Launches World’s First National Wildfire Satellite System with OroraTech https://ml.globenewswire.com/media/f405d4dd-2633-4e23-8086-bbaa6bf83b25/medium/ororatech-s-hellenic-fire-system.jpg https://www.surinamehealthcarepress.com/article/910253114-aura-biosciences-announces-pricing-of-260-million-public-offering-of-common-stock-and-pre-funded-warrants Suriname Healthcare Press en PressRelease 2026-05-04T13:03:06+00:00 Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.surinamehealthcarepress.com/article/910252862-carnosyn-brands-expands-tribsyn-applications-across-beverage-dairy-and-medical-nutrition Suriname Healthcare Press en PressRelease 2026-05-04T13:00:00+00:00 CarnoSyn® Brands Expands TriBsyn® Applications Across Beverage, Dairy, and Medical Nutrition https://ml.globenewswire.com/media/4b40dd5b-0137-41f8-83de-422e4b4f3196/small/nai-full-logo-green2-0-png.png https://www.surinamehealthcarepress.com/article/910252869-oncolytics-biotech-reports-durable-responses-in-second-line-ras-mutant-mss-colorectal-cancer Suriname Healthcare Press en PressRelease 2026-05-04T13:00:00+00:00 Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer https://ml.globenewswire.com/media/f0121259-b2be-4290-90a3-0d2c3b243aed/small/oncolytics-biotech-jpg.jpg https://www.surinamehealthcarepress.com/article/910252878-curated-digital-health-works-now-there-s-a-claims-study-to-prove-it Suriname Healthcare Press en PressRelease 2026-05-04T13:00:00+00:00 Curated Digital Health Works; Now There’s a Claims Study to Prove It https://ml.globenewswire.com/media/b8d88974-2aeb-4baa-ad3b-2ab758ed4dd9/small/solera-main-logo-red-png.png https://www.surinamehealthcarepress.com/article/910252958-biomogging-brings-research-backed-rigour-to-looksmaxxing-as-the-discipline-goes-mainstream Suriname Healthcare Press en PressRelease 2026-05-04T13:00:00+00:00 BioMogging Brings Research-Backed Rigour to Looksmaxxing as the Discipline Goes Mainstream https://ml.globenewswire.com/media/70c5dbfa-bae7-4e93-ac79-cd20cb471a59/medium/biomogging-brings-research-backed-rigour-to-looksmaxxing-as.png https://www.surinamehealthcarepress.com/article/910252971-fate-therapeutics-announces-three-presentations-at-the-2026-asgct-annual-meeting-highlighting-off-the-shelf-car-t-cell-therapy-pipeline-for-cancer-and Suriname Healthcare Press en PressRelease 2026-05-04T13:00:00+00:00 Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg https://www.surinamehealthcarepress.com/article/910253043-gyre-therapeutics-completes-acquisition-of-cullgen-to-create-u-s-and-china-based-fully-integrated-biopharmaceutical-company Suriname Healthcare Press en PressRelease 2026-05-04T12:47:47+00:00 Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company https://ml.globenewswire.com/media/24951768-57e9-4d7a-b969-f00258b17136/small/gyre-logo-png.png https://www.surinamehealthcarepress.com/article/910252933-cannabix-technologies-announces-delivery-of-marijuana-breath-test-mbt-to-workplace-drug-and-alcohol-testing-clinic Suriname Healthcare Press en PressRelease 2026-05-04T12:45:00+00:00 Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Workplace Drug and Alcohol Testing Clinic https://ml.globenewswire.com/media/72457dcd-4783-441b-b82d-641591cd1f13/medium/cannabix-technologies-inc.jpg https://www.surinamehealthcarepress.com/article/910253010-polyrizon-announces-u-s-patent-expansion-for-its-intranasal-drug-delivery-platform Suriname Healthcare Press en PressRelease 2026-05-04T12:45:00+00:00 Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform https://ml.globenewswire.com/media/YWIxMzIzNDgtN2UwNy00NTAyLThjZDMtZWMwNGFjZTdmNWJhLTUwMDEyOTIyMy0yMDI2LTA1LTA0LWVu/tiny/Polyrizon-Ltd-.png https://www.surinamehealthcarepress.com/article/910247536-brainway-launches-personalized-anti-procrastination-app-grounded-in-cbt-earns-6-000-user-reviews Suriname Healthcare Press en PressRelease 2026-05-04T12:30:00+00:00 Brainway Launches Personalized Anti-Procrastination App Grounded in CBT, Earns 6,000+ User Reviews https://ml-eu.globenewswire.com/media/59f7037f-6f10-4f4b-9b8f-6a7b25f61828/medium/brainway-smarter-focus-built-around-you.png https://www.surinamehealthcarepress.com/article/910247553-mapi-pharma-explores-u-s-aseptic-manufacturing-facility-to-support-growing-demand-for-aseptic-and-long-acting-generic-and-innovative-injectables Suriname Healthcare Press en PressRelease 2026-05-04T12:30:00+00:00 Mapi Pharma Explores U.S. Aseptic Manufacturing Facility to Support Growing Demand for Aseptic and Long-Acting Generic and innovative Injectables https://ml.globenewswire.com/media/a15e698a-0f26-4d44-bf6a-78b7ae34d25d/small/mapi-pharma-logo-png.png https://www.surinamehealthcarepress.com/article/910247597-abeona-therapeutics-announces-date-of-first-quarter-financial-results Suriname Healthcare Press en PressRelease 2026-05-04T12:30:00+00:00 Abeona Therapeutics® Announces Date of First Quarter Financial Results https://ml.globenewswire.com/media/f11f9f14-9744-4666-aef3-9771488c41bd/small/thumb-1740-12-silhouette-vertical-full-color-png.png https://www.surinamehealthcarepress.com/article/910247598-sienna-continues-platform-growth Suriname Healthcare Press en PressRelease 2026-05-04T12:30:00+00:00 Sienna Continues Platform Growth https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://www.surinamehealthcarepress.com/article/910247606-dentsply-sirona-launches-smart-view-detect-world-s-first-fda-cleared-ai-enabled-diagnostic-aid-for-detecting-teeth-with-periapical-radiolucencies Suriname Healthcare Press en PressRelease 2026-05-04T12:30:00+00:00 Dentsply Sirona Launches Smart View - Detect, World’s First FDA-Cleared AI-enabled diagnostic aid for detecting teeth with Periapical Radiolucencies in CBCTs https://ml.globenewswire.com/media/91e36dfa-44e3-4905-a186-3a988bd67ab8/small/dentsply-sirona-grey-80-black-rgb-jpg.JPG https://www.surinamehealthcarepress.com/article/910247610-fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial Suriname Healthcare Press en PressRelease 2026-05-04T12:30:00+00:00 FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://www.surinamehealthcarepress.com/article/910247613-bicara-therapeutics-to-report-first-quarter-2026-financial-results-and-business-updates-on-may-11-2026-at-8-30-am-et Suriname Healthcare Press en PressRelease 2026-05-04T12:30:00+00:00 Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET https://ml.globenewswire.com/media/fdf5e06f-0748-428a-8f90-b0a1c6f7bdf3/small/bicara-logo-struck-png.png https://www.surinamehealthcarepress.com/article/910247630-fortress-biotech-to-participate-in-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference Suriname Healthcare Press en PressRelease 2026-05-04T12:30:00+00:00 Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference https://ml.globenewswire.com/media/d82bf2ce-81b7-4989-9e6b-08e6bb6e1f95/small/fortressbio1-jpg.jpg https://www.surinamehealthcarepress.com/article/910247674-newgen-provides-update-on-fiscal-year-2025-results-and-strategic-progress Suriname Healthcare Press en PressRelease 2026-05-04T12:30:00+00:00 NewGen Provides Update on Fiscal Year 2025 Results and Strategic Progress https://ml.globenewswire.com/media/ZWQwY2VjNmQtYTdlZi00YTUxLTg3NmItMmI3OWVkMTQ5MGQ4LTEyOTcwMTEtMjAyNi0wNS0wNC1lbg==/tiny/NewGenIvf-Limited.png https://www.surinamehealthcarepress.com/article/910242525-serefin-health-launches-mycaresteps-program-to-support-care-coordination-across-grey-bruce Suriname Healthcare Press en PressRelease 2026-05-04T12:05:00+00:00 Serefin Health Launches MyCareSteps Program to Support Care Coordination Across Grey Bruce https://ml.globenewswire.com/media/NmJiMmQwN2MtYTlmMi00Njc1LTk1N2QtNmZlYzk1MDJkMTc3LTEzMjMwMzktMjAyNi0wNS0wNC1lbg==/tiny/Serefin-Inc.png https://www.surinamehealthcarepress.com/article/910242598-candel-therapeutics-to-host-investor-conference-call-following-presentation-of-extended-data-from-phase-3-trial-of-aglatimagene-besadenovec-in Suriname Healthcare Press en PressRelease 2026-05-04T12:05:00+00:00 Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting https://ml.globenewswire.com/media/8b82e1e3-4a67-4472-a7c8-05f9d24c9bb0/small/candel-logo-fullcolor-4-png.png https://www.surinamehealthcarepress.com/article/910242367-proqr-announces-annual-general-meeting-of-shareholders-to-be-held-june-2-2026 Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png https://www.surinamehealthcarepress.com/article/910242370-dr-falk-pharma-and-renexxion-announce-positive-results-on-naronapride-in-gastroparesis-from-the-global-phase-2b-move-it-trial Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial https://ml-eu.globenewswire.com/media/7cf77d4a-25b5-4471-a282-0334907cbfbd/small/falk-logo-rgb-jpg.jpg https://www.surinamehealthcarepress.com/article/910242372-dr-falk-pharma-and-renexxion-announce-positive-results-on-naronapride-in-gastroparesis-from-the-global-phase-2b-move-it-trial Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial https://ml-eu.globenewswire.com/media/540f0a78-db35-42ad-9e90-7b81e8ff3ad6/small/renirl-logo-png.png https://www.surinamehealthcarepress.com/article/910242373-cptx-to-present-preclinical-proof-of-principle-of-its-dna-based-in-vivo-car-t-platform-at-asgct-annual-meeting Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 CPTx to present preclinical proof-of-principle of its DNA-based in vivo CAR T platform at ASGCT Annual Meeting https://ml-eu.globenewswire.com/media/b3ec9ca7-8866-466a-9d91-09342002e341/small/cptx-logo-high-res-png.png https://www.surinamehealthcarepress.com/article/910242419-evaxion-to-announce-business-update-and-first-quarter-2026-financial-results-on-may-7-2026 Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026 https://ml-eu.globenewswire.com/media/19d0d69c-7f37-4d3b-8f26-2866d4ec3311/small/evaxion-deepblue-rgb-png.png https://www.surinamehealthcarepress.com/article/910242435-recludix-pharma-announces-upcoming-oral-presentations-on-preclinical-data-for-oral-stat6-inhibitor-rex-8756-and-topical-stat-1-3-inhibitors-at-the Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting https://ml.globenewswire.com/media/NDM5ZGUzYTItNGI0Zi00N2Y3LWE3Y2QtZmViNDYyN2I1ZWRjLTEyMzYyMjItMjAyNi0wNS0wNC1lbg==/tiny/Recludix-Pharma-Inc-.png https://www.surinamehealthcarepress.com/article/910242438-rhythm-pharmaceuticals-announces-new-data-presentations-in-acquired-hypothalamic-obesity-at-pediatric-endocrine-society Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society https://ml.globenewswire.com/media/b767aaa5-9915-465f-9233-d97757f4e387/small/rhythm-logo-rgb-jpg-registration-mark-jpg.jpg https://www.surinamehealthcarepress.com/article/910242442-spur-therapeutics-presents-clinical-insights-on-bone-disease-impact-of-flt201-in-adults-with-gaucher-disease-type-1 Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1 https://ml.globenewswire.com/media/195ccecc-f977-4fb5-ba01-43af7ec47589/small/spur-therapeutics-black-wopacity-rgb-png.png https://www.surinamehealthcarepress.com/article/910242449-kyverna-therapeutics-appoints-nadia-dac-seasoned-commercial-leader-in-neurology-and-rare-disease-as-chief-commercial-officer Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer https://ml.globenewswire.com/media/c166e9f5-941a-48b0-be17-c24d54785784/small/kyverna-primary-full-2-png.png https://www.surinamehealthcarepress.com/article/910242457-4dmt-to-participate-in-upcoming-investor-conferences Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 4DMT to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/027d40cf-145a-47b2-a0b8-823759376823/small/logo-2x-png.png https://www.surinamehealthcarepress.com/article/910242470-valitor-presents-preclinical-data-demonstrating-superior-durability-with-six-month-treatment-protocol-of-vltr-559-to-treat-wet-amd Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Valitor Presents Preclinical Data Demonstrating Superior Durability with Six-month Treatment Protocol of VLTR-559 to Treat Wet AMD https://ml.globenewswire.com/media/58da3c80-c616-4358-9bbe-2936ace96649/small/valitor-sidebyside-png.png https://www.surinamehealthcarepress.com/article/910242492-nanox-announces-distribution-agreement-with-nuviodx-to-support-deployment-of-nanox-arc-systems Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Nanox Announces Distribution Agreement with NuvioDx to Support Deployment of Nanox.ARC Systems https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg https://www.surinamehealthcarepress.com/article/910242493-bascom-palmer-eye-institute-presents-four-posters-on-rose-bengal-photodynamic-antimicrobial-therapy-at-arvo-2026-advancing-the-clinical-case-for Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis https://ml.globenewswire.com/media/7cd1d796-f4d3-43f7-8e2b-eb51dc04a073/small/new-logo-png.png https://www.surinamehealthcarepress.com/article/910242515-healthlynked-launches-new-consumer-platform-and-multi-site-digital-ecosystem-to-redefine-the-front-door-to-healthcare Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 HealthLynked Launches New Consumer Platform and Multi-Site Digital Ecosystem to Redefine the Front Door to Healthcare https://ml.globenewswire.com/media/d46cdad7-4537-49b8-bd75-54331ac4ff32/small/get-better-faster-png.png https://www.surinamehealthcarepress.com/article/910242538-lifeward-announces-new-rewalk-data-presented-at-asia-2026-conference-demonstrating-a-comprehensive-longitudinal-safety-analysis-for-a-powered Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton https://ml.globenewswire.com/media/9343d7ac-5bc7-4a60-a2c9-a41bf7b5e007/small/lifeward-full-logo-rgb-for-web-01-jpg.jpg https://www.surinamehealthcarepress.com/article/910242561-lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference https://ml.globenewswire.com/media/e058841a-d17f-4fd7-b817-0b2c8e6cb656/small/lenz-png.png https://www.surinamehealthcarepress.com/article/910242564-atsena-presents-positive-interim-six-month-results-from-part-b-of-phase-1-2-3-lighthouse-trial-evaluating-atsn-201-in-patients-with-x-linked Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Atsena Presents Positive Interim Six-Month Results from Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis https://ml.globenewswire.com/media/90d0bd84-4404-435c-9875-3473b4cc7172/small/atsena-logo-jpg.jpg https://www.surinamehealthcarepress.com/article/910242574-after-successful-fda-meeting-clene-filing-accelerated-approval-nda-for-als Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS https://ml.globenewswire.com/media/e9de96a4-582e-4975-8e43-6f3e6259c075/small/clene-logo-2x-png.png https://www.surinamehealthcarepress.com/article/910242578-akebia-therapeutics-announces-vadadustat-post-hoc-win-statistics-analysis-demonstrating-statistically-significant-reduction-in-mortality-and Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.surinamehealthcarepress.com/article/910242582-legend-biotech-expands-scientific-advisory-expertise-to-inform-future-growth Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth https://ml.globenewswire.com/media/d3a680c2-cab6-4eb2-9ed0-7be055f9e180/small/legend-logo-fullcolor-transparent-1-png.png https://www.surinamehealthcarepress.com/article/910242619-senseonics-enters-into-amended-loan-agreement-with-hercules-to-increase-borrowing-capacity-to-140-million Suriname Healthcare Press en PressRelease 2026-05-04T12:00:00+00:00 Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million https://ml.globenewswire.com/media/7f64f449-dd5d-4bd1-9504-82adb3846669/small/logo-png.png https://www.surinamehealthcarepress.com/article/910237928-emerging-drugs-market-to-reach-558-0-billion-by-2030-driven-by-biologics-innovation-and-regulatory-support Suriname Healthcare Press en PressRelease 2026-05-04T11:34:01+00:00 Emerging Drugs Market to Reach $558.0 Billion by 2030, Driven by Biologics Innovation and Regulatory Support https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.surinamehealthcarepress.com/article/910237828-vera-therapeutics-to-participate-in-the-bank-of-america-securities-2026-health-care-conference Suriname Healthcare Press en PressRelease 2026-05-04T11:30:00+00:00 Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference https://ml.globenewswire.com/media/b5c9081c-e6d9-44f7-abd0-0997a3c713f2/small/vera-thumbnail-jpg.jpg https://www.surinamehealthcarepress.com/article/910237832-macrogenics-and-sagard-healthcare-partners-enter-into-expanded-zynyz-royalty-purchase-agreement Suriname Healthcare Press en PressRelease 2026-05-04T11:30:00+00:00 MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement https://ml.globenewswire.com/media/72a7b58c-b7ca-4cd5-b2bb-185124351f1c/small/macrogenics-logo-transparent-background-png.png https://www.surinamehealthcarepress.com/article/910237835-entente-education-canada-honours-dr-roger-wong-with-award-for-eminent-contribution-to-older-adults-in-canada Suriname Healthcare Press en PressRelease 2026-05-04T11:30:00+00:00 Entente Education Canada honours Dr. Roger Wong with Award for Eminent Contribution to Older Adults in Canada https://ml.globenewswire.com/media/YzNlOWZkNDctZThiZC00MzJjLTg2MmItM2U3ZTNhNzViYzJhLTUwMDE2MjAyOC0yMDI2LTA1LTA0LWVu/tiny/Entente-Education-Canada.png https://www.surinamehealthcarepress.com/article/910237841-bridgebio-to-present-new-acoramidis-data-on-disease-progression-biomarkers-and-clinical-outcomes-at-esc-heart-failure-2026 Suriname Healthcare Press en PressRelease 2026-05-04T11:30:00+00:00 BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 https://ml.globenewswire.com/media/2074ba9b-0e5b-41fa-baac-553f1345bb75/small/bridge-bio-black-png.png https://www.surinamehealthcarepress.com/article/910237849-kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Suriname Healthcare Press en PressRelease 2026-05-04T11:30:00+00:00 Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/ebf510d7-3727-4cc8-894f-6ce2d82b941a/small/kura-logo-for-globe-newswire-prs-png.png https://www.surinamehealthcarepress.com/article/910237860-palvella-therapeutics-announces-first-patients-dosed-in-phase-2-lotu-trial-of-fast-track-designated-qtorin-rapamycin-for-clinically-significant Suriname Healthcare Press en PressRelease 2026-05-04T11:30:00+00:00 Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas https://ml.globenewswire.com/media/83fd569b-5e6c-46ad-882a-6430f8ab755a/small/palvella-2025-logo-new-jpg.jpg https://www.surinamehealthcarepress.com/article/910237878-inflarx-reports-favorable-reactive-metabolite-profile-for-izicopan-in-human-liver-microsomes Suriname Healthcare Press en PressRelease 2026-05-04T11:30:00+00:00 InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes https://ml.globenewswire.com/media/e017df5c-9a9b-4f4f-9a94-6c2eeb0400bc/small/inflarx-logo-png.png https://www.surinamehealthcarepress.com/article/910237911-windward-bio-announces-165m-crossover-financing-to-advance-pipeline-of-long-acting-immunology-therapies-with-best-in-disease-potential Suriname Healthcare Press en PressRelease 2026-05-04T11:30:00+00:00 Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential https://ml.globenewswire.com/media/Nzk5NDkzNGQtNWZiNi00MGZkLTg2ZTAtYzViNDkwNTJjOTVmLTUwMDEzMTYxMS0yMDI2LTA1LTA0LWVu/tiny/Windward-Bio.png https://www.surinamehealthcarepress.com/article/910237843-cartesian-therapeutics-announces-new-employment-inducement-grants Suriname Healthcare Press en PressRelease 2026-05-04T11:05:00+00:00 Cartesian Therapeutics Announces New Employment Inducement Grants https://ml.globenewswire.com/media/2bf78841-be30-4bb5-bfb5-0b5f383f3302/small/cartesian-logo-color-png.png https://www.surinamehealthcarepress.com/article/910237845-nextcure-and-simcere-zaiming-initiate-dose-optimization-for-sim0505-cdh6-adc-in-gynecologic-cancers Suriname Healthcare Press en PressRelease 2026-05-04T11:05:00+00:00 NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers https://ml.globenewswire.com/media/df24cd65-0f3d-4ede-9e7a-c3f58ce6e9d4/small/logo-nextcure-jpg.jpg https://www.surinamehealthcarepress.com/article/910237870-kraig-biocraft-laboratories-launches-april-may-production-cycle-following-record-spider-silk-output Suriname Healthcare Press en PressRelease 2026-05-04T11:05:00+00:00 Kraig Biocraft Laboratories Launches April/May Production Cycle Following Record Spider Silk Output https://ml.globenewswire.com/media/3cf5ab91-0822-460b-bb13-17447941c84a/small/kblb-logo-jpg.jpg https://www.surinamehealthcarepress.com/article/910233626-pasithea-therapeutics-announces-appointment-of-kartik-krishnan-m-d-ph-d-as-chief-medical-officer Suriname Healthcare Press en PressRelease 2026-05-04T11:01:00+00:00 Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer https://ml.globenewswire.com/media/0016f128-13c3-45a7-8455-cec1f4768995/small/pasithealogo-png.png https://www.surinamehealthcarepress.com/article/910233519-ardena-strengthens-executive-team-to-drive-its-next-phase-of-growth Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 Ardena Strengthens Executive Team to Drive its Next Phase of Growth https://ml-eu.globenewswire.com/media/eddef504-18ee-4f10-8442-9e61ef77e262/medium/ardena-appoints-cfo-and-cco.png https://www.surinamehealthcarepress.com/article/910233520-indivior-announces-175-million-accelerated-share-repurchase Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 Indivior Announces $175 Million Accelerated Share Repurchase https://ml-eu.globenewswire.com/media/42de3285-90ea-4020-a3ad-25f71026b41a/small/indivior-logo-jpg.jpg https://www.surinamehealthcarepress.com/article/910233590-biocryst-announces-european-licensing-agreement-with-irish-affiliate-of-neopharmed-gentili-for-navenibart-in-hereditary-angioedema Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg https://www.surinamehealthcarepress.com/article/910233621-tenax-therapeutics-appoints-timothy-healey-mba-as-chief-commercial-officer Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer https://ml.globenewswire.com/media/d8c1d3b1-51a5-4835-a9e8-6d5bce14917e/small/tenax-logo-rgb-color-jpg.jpg https://www.surinamehealthcarepress.com/article/910233623-netramark-appoints-dr-panteli-theocharous-as-fractional-chief-medical-officer-strengthening-clinical-leadership-to-accelerate-global-adoption-of Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI https://ml.globenewswire.com/media/d65cf3f8-cf9c-475c-b740-09a659269da4/small/netramark-word-eye-blk-jpg.jpg https://www.surinamehealthcarepress.com/article/910233629-krystal-biotech-announces-first-quarter-2026-financial-and-operating-results Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 Krystal Biotech Announces First Quarter 2026 Financial and Operating Results https://ml.globenewswire.com/media/94ec1f39-c0eb-4e65-9d7e-250519ef03f4/small/krys-logo-nobackground-with-registered-symbol-png.png https://www.surinamehealthcarepress.com/article/910233642-10-barrel-brewing-launches-clean-slate-and-salty-sips-expanding-rtd-line-with-functional-n-a-and-low-sugar-cocktails Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 10 Barrel Brewing Launches Clean Slate and Salty Sips, Expanding RTD Line with Functional N/A and Low-Sugar Cocktails https://ml.globenewswire.com/media/5e71b27b-1cc8-4780-8689-8d8d6ae86236/medium/clean-slate-and-salty-sips.png https://www.surinamehealthcarepress.com/article/910233645-seres-therapeutics-presents-preclinical-data-at-digestive-disease-week-ddw-2026-supporting-ser-603-a-next-generation-cultivated-live-biotherapeutic Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.surinamehealthcarepress.com/article/910233649-centrum-launches-newly-reformulated-adults-50-complete-multivitamin-with-clinically-shown-cognitive-benefits Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 Centrum Launches Newly Reformulated Adults 50+ Complete Multivitamin with Clinically Shown Cognitive Benefits https://ml.globenewswire.com/media/395df94a-8079-4f58-9b54-df434e56ec33/medium/centrum-adults-50-complete-multivitamin.png https://www.surinamehealthcarepress.com/article/910233653-centrum-lance-sa-multivitamine-compl-te-adultes-50-nouvellement-reformul-e-avec-des-bienfaits-cognitifs-d-montr-s-cliniquement Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 Centrum lance sa multivitamine complète Adultes 50+ nouvellement reformulée avec des bienfaits cognitifs démontrés cliniquement https://ml.globenewswire.com/media/abbbfaf3-e52b-413c-9ded-52f74cf50911/medium/centrum-multivitamine-complete-pour-adultes-50.png https://www.surinamehealthcarepress.com/article/910233661-genyro-announces-new-paper-demonstrating-how-sidewinder-technology-democratizes-dna-construction-at-scale-and-facilitates-ai-driven-protein-design Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 Genyro Announces New Paper Demonstrating How Sidewinder Technology Democratizes DNA Construction at Scale and Facilitates AI-Driven Protein Design https://ml.globenewswire.com/media/346f123b-cc5d-4de0-a31f-9c4f1315c070/medium/genyro-co-founders.jpg https://www.surinamehealthcarepress.com/article/910233678-seer-announces-appointment-of-anthony-bazarko-as-chief-commercial-officer Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer https://ml.globenewswire.com/media/ecdddbc3-8a58-4cba-a4a1-33971e79339a/medium/anthony-bazarko.jpg https://www.surinamehealthcarepress.com/article/910233683-istios-health-partners-with-care-id-to-expand-national-infectious-disease-clinical-research-network Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 Istios Health Partners with CARE-ID to Expand National Infectious Disease Clinical Research Network https://ml.globenewswire.com/media/MTI0OGVmYTMtNmZkNC00ODA4LWJlNzUtNTYxODJlODcxNDBmLTEzMTYxMjEtMjAyNi0wNS0wNC1lbg==/tiny/Istios-Health.png https://www.surinamehealthcarepress.com/article/910233687-adma-biologics-announces-fda-approval-to-expand-the-label-for-asceniv-to-include-pediatric-immune-compromised-patients-two-years-of-age-and-older Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg https://www.surinamehealthcarepress.com/article/910233701-axsome-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update Suriname Healthcare Press en PressRelease 2026-05-04T11:00:00+00:00 Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update https://ml.globenewswire.com/media/1186f248-bfb6-4258-a391-f2ffd94c5d76/small/axsome-r-morpheus-logo-pos-rgb-png.png https://www.surinamehealthcarepress.com/article/910233704-cabaletta-bio-announces-pricing-of-150-million-underwritten-offering Suriname Healthcare Press en PressRelease 2026-05-04T10:35:54+00:00 Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering https://ml.globenewswire.com/media/44175396-6bbb-435f-b037-54a4052160d4/small/cabaletta-bio-registered-logo-png.png https://www.surinamehealthcarepress.com/article/910224348-aura-biosciences-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants Suriname Healthcare Press en PressRelease 2026-05-04T10:03:00+00:00 Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.surinamehealthcarepress.com/article/910224335-aura-biosciences-announces-ceo-transition-as-company-advances-phase-3-compass-trial-toward-enrollment-completion Suriname Healthcare Press en PressRelease 2026-05-04T10:01:00+00:00 Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.surinamehealthcarepress.com/article/910224339-holland-bloorview-kids-rehabilitation-hospital-receives-475-000-commitment-from-td-bank-group-to-support-youth-with-disabilities Suriname Healthcare Press en PressRelease 2026-05-04T10:00:00+00:00 Holland Bloorview Kids Rehabilitation Hospital receives $475,000 commitment from TD Bank Group to support youth with disabilities https://ml.globenewswire.com/media/YjY1NmY0MjktNjNkNy00MjI4LTgwNDYtZWJjZmRmYTgyZmI0LTExMDQ5NDUtMjAyNi0wNS0wNC1lbg==/tiny/Holland-Bloorview-Kids-Rehabil.png https://www.surinamehealthcarepress.com/article/910224345-scilex-holding-company-announces-its-board-of-directors-approved-may-26-2026-as-the-payment-date-of-the-previously-announced-dividend-of-dream-bowl Suriname Healthcare Press en PressRelease 2026-05-04T10:00:00+00:00 Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the… https://ml.globenewswire.com/media/e2f985bf-0880-4d05-8838-90a69c888cf9/small/logo-jpg.jpg https://www.surinamehealthcarepress.com/article/910220606-mother-s-day-gifting-is-changing-from-symbolic-presents-to-meaningful-relief-bob-and-brad-marks-the-occasion-with-up-to-30-off-wellness-devices Suriname Healthcare Press en PressRelease 2026-05-04T09:10:38+00:00 Mother’s Day Gifting Is Changing: From Symbolic Presents to Meaningful Relief — Bob and Brad Marks the Occasion with Up to 30% Off Wellness Devices https://ml.globenewswire.com/media/b55bca4c-0fac-4226-9f7d-2e4b7b3e94e0/medium/mother-s-day-gifts-2026.png https://www.surinamehealthcarepress.com/article/910150844-novelty-nobility-taps-agc-biologics-to-further-develop-bispecific-drug-candidate Suriname Healthcare Press en PressRelease 2026-05-04T00:00:00+00:00 Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate https://ml.globenewswire.com/media/cecf4f80-22df-4bbf-b0a7-f50b9acf9495/medium/agc-biologics-and-novelty-nobility-representatives-meet.png https://www.surinamehealthcarepress.com/article/910150881-agc Suriname Healthcare Press en PressRelease 2026-05-04T00:00:00+00:00 ノベルティ・ノビリティ、AGCバイオロジクスと提携し、二重特異性抗体候補薬の開発を推進 https://ml.globenewswire.com/media/NWUzMzQxMTYtZjcyYS00YjQ4LWE2ODYtY2ZiNWE0YTlmM2MzLTEzMTU5MjMtMjAyNi0wNS0wNC1qYQ==/tiny/AGC-Biologics-Inc-.png https://www.surinamehealthcarepress.com/article/910150885-novelty-nobility-agc-biologics Suriname Healthcare Press en PressRelease 2026-05-04T00:00:00+00:00 노벨티 노빌리티 (Novelty Nobility), 이중특이성 항체 개발 위해 AGC Biologics와 협력 확대 https://ml.globenewswire.com/media/NWUzMzQxMTYtZjcyYS00YjQ4LWE2ODYtY2ZiNWE0YTlmM2MzLTEzMTU5MjMtMjAyNi0wNS0wNC1rbw==/tiny/AGC-Biologics-Inc-.png https://www.surinamehealthcarepress.com/article/910117015-caphra-urges-policymakers-to-expand-the-tobacco-cessation-toolkit Suriname Healthcare Press en PressRelease 2026-05-03T19:00:00+00:00 CAPHRA Urges Policymakers to Expand the Tobacco Cessation Toolkit https://ml.globenewswire.com/media/6dc95f2d-65fb-409f-aed4-9ebe55554004/small/picture1-png.png https://www.surinamehealthcarepress.com/article/909983104-northeast-ohio-medical-university-neomed-celebrates-306-new-graduates-at-commencement-ceremony Suriname Healthcare Press en PressRelease 2026-05-02T22:07:03+00:00 Northeast Ohio Medical University (NEOMED) Celebrates 306 New Graduates at Commencement Ceremony https://ml.globenewswire.com/media/MDgwNDNmM2ItZGZiNi00NTRjLTgzZTUtMDg3MjZjNjY0NGIyLTUwMDE1MDkxOS0yMDI2LTA1LTAyLWVu/tiny/Northeast-Ohio-Medical-Univers.png https://www.surinamehealthcarepress.com/article/909978301-memopryl-gets-reviewed-complete-formula-evaluation-of-ingredient-claims-and-side-effects-risk Suriname Healthcare Press en PressRelease 2026-05-02T21:25:47+00:00 MemoPryl Gets Reviewed: Complete Formula Evaluation of Ingredient Claims and Side Effects Risk https://zingfast.com/wp-content/uploads/2026/05/MemoPryl-Reviews.jpg